Despite clear guidelines promoting cautious, individualized care – especially for frail older adults and nursing home residents – these complications remain alarmingly common.
Joseph G. Ouslander, M.D., a professor of geriatric medicine at Florida Atlantic University’s Charles E. Schmidt College of Medicine, and his collaborator, have published a paper in the Journal of the American Geriatrics Society calling for urgent change in how health care providers are supported and held accountable. They argue that physicians, nurse practitioners, and physician assistants prescribing diabetes and hypertension medications should be actively encouraged – not merely expected – to avoid overtreatment through carefully designed quality measures.
“These preventable complications, including dangerously low blood sugar and blood pressure, often result from well-intended medical care that overlooks a patients’ age, health status, or life expectancy,” said Ouslander, senior author. “We need better approaches that reward appropriate, personalized care. These measures should prioritize safe, evidence-based, personalized care rather than rigid targets that can cause harm.”
Ouslander and Michael Wasserman, M.D., co-author and geriatrician with the California Association of Long-Term Care, emphasize that clinical guidelines are crucial in preventing treatment-related harms like low blood sugar and blood pressure in older adults. For diabetes, major organizations such as the American Diabetes Association recommend more relaxed blood sugar targets (and higher HbA1c levels) for older adults with poor health or multiple conditions to minimize hypoglycemia risk. Yet, many vulnerable older adults continue to be overtreated. Updated long-term care guidelines also caution against overly strict diets, sliding-scale insulin, and medications that raise the risk of hypoglycemia.
For high blood pressure, several guidelines recommend moderate targets (systolic 130-150) even for those over age 80. However, since most clinical trials exclude frail or nursing home residents, the researchers advocate for a personalized approach that carefully balances each patient’s risks, benefits and goals.
The researchers reference the well-known SPRINT trial, which demonstrated that aggressive blood pressure control can reduce hypertension-related risks. Yet, the trial excluded nearly all medically vulnerable older adults – such as those in nursing homes or with diabetes, dementia, prior strokes, or serious illnesses – meaning its results may not be applicable to those most vulnerable to harm from intensive treatment.
In their review, Ouslander and Wasserman offer several general and specific recommendations for strategies that they believe have the potential to reduce the incidence of medically caused hypoglycemia and hypotension and related complications in vulnerable older adults.
Among their key recommendations:
Test new treatments: Study newer medications and technologies that may be safer and more effective for older adults. Prioritize quality improvement: Support programs that enhance diabetes and hypertension care in clinics and nursing homes. Use data to target risks: Leverage health records and claims data to identify and address causes of hypoglycemia and hypotension. Document individualized care plans: Clearly record shared decision-making tailored to patient health, preferences, and life expectancy. Foster cross-disciplinary collaboration: Engage researchers, policymakers, and clinicians to develop practical and affordable safety strategies. Develop new quality metrics: Track medication overuse and adverse events, sharing data to incentivize safer care. Conduct more research: Prioritize clinical trials and real-world studies to find the best strategies for vulnerable older adults. “To truly protect vulnerable older adults from preventable harm, we must rethink how we manage chronic conditions like diabetes and hypertension,” said Ouslander. “This means moving beyond one-size-fits-all targets to evidence-based, personalized treatment plans shaped by shared decision-making, supported by appropriate technology, and backed by policies prioritizing patient safety over rigid metrics. It’s not just a clinical challenge – it’s a moral imperative that requires collaboration to develop smarter, safer and more person-centered care that reduces hospitalizations, improves outcomes and honors the dignity of those most at risk.”
- FAU -
About the Charles E. Schmidt College of Medicine:
Florida Atlantic University’s Charles E. Schmidt College of Medicine is one of approximately 159 accredited medical schools in the U.S. The college was launched in 2010, when the Florida Board of Governors made a landmark decision authorizing FAU to award the M.D. degree. After receiving approval from the Florida legislature and the governor, it became the 134th allopathic medical school in North America. With more than 170 full and part-time faculty and more than 1,400 affiliate faculty, the college matriculates 80 medical students each year and has been nationally recognized for its innovative curriculum. The college offers M.S. (thesis and non-thesis) and Ph.D. programs in biomedical science, along with a certificate in genomics and precision medicine. Taught by top researchers, the curriculum combines cutting-edge coursework with hands-on learning, preparing graduates for careers in medicine, research, industry, and academia. To further Florida Atlantic’s commitment to increase much needed medical residency positions in Palm Beach County and to ensure that the region will continue to have an adequate and well-trained physician workforce, the FAU Charles E. Schmidt College of Medicine Consortium for Graduate Medical Education (GME) was formed in fall 2011 with five leading hospitals in Palm Beach County. The consortium currently has five Accreditation Council for Graduate Medical Education (ACGME) accredited residencies including internal medicine, surgery, emergency medicine, psychiatry, and neurology, and five fellowships in cardiology, hospice and palliative care, geriatrics, vascular surgery, and pulmonary disease and critical care medicine. The college also manages the Florida Atlantic University Medical Group, offering comprehensive primary care, and the Marcus Institute of Integrative Health specializes in integrative pain management, precision therapies, and mental health.
About Florida Atlantic University:
Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, Florida Atlantic serves more than 30,000 undergraduate and graduate students across six campuses located along the Southeast Florida coast. In recent years, the University has doubled its research expenditures and outpaced its peers in student achievement rates. Through the coexistence of access and excellence, Florida Atlantic embodies an innovative model where traditional achievement gaps vanish. Florida Atlantic is designated as a Hispanic-serving institution, ranked as a top public university by U.S. News & World Report, and holds the designation of “R1: Very High Research Spending and Doctorate Production” by the Carnegie Classification of Institutions of Higher Education. Florida Atlantic shares this status with less than 5% of the nearly 4,000 universities in the United States. For more information, visit www.fau.edu.
END